GSK (LON:GSK) Receives “Buy” Rating from Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “buy” rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Wednesday, Marketbeat reports. They presently have a GBX 1,950 ($24.27) price target on the stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential upside of 23.14% from the company’s previous close.

GSK has been the subject of a number of other reports. Barclays reissued an “equal weight” rating and set a GBX 1,725 ($21.47) target price on shares of GSK in a research note on Monday, April 8th. Shore Capital reiterated a “buy” rating on shares of GSK in a research report on Thursday, March 7th. Finally, Berenberg Bank boosted their target price on shares of GSK from GBX 1,650 ($20.54) to GBX 1,820 ($22.66) and gave the stock a “buy” rating in a research report on Wednesday, February 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of GBX 1,630.63 ($20.30).

GSK Stock Down 0.4 %

Shares of LON:GSK opened at GBX 1,583.50 ($19.71) on Wednesday. GSK has a fifty-two week low of GBX 1,302.60 ($16.22) and a fifty-two week high of GBX 1,719.80 ($21.41). The company has a quick ratio of 0.73, a current ratio of 0.88 and a debt-to-equity ratio of 140.82. The firm’s 50-day simple moving average is GBX 1,662.39 and its 200-day simple moving average is GBX 1,545.33. The company has a market cap of £64.77 billion, a price-to-earnings ratio of 1,319.58, a PEG ratio of 1.09 and a beta of 0.27.

Insider Buying and Selling

In other GSK news, insider Emma Walmsley sold 139,792 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.64), for a total transaction of £2,317,751.36 ($2,885,287.39). In other GSK news, insider Emma Walmsley sold 139,792 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.64), for a total value of £2,317,751.36 ($2,885,287.39). Also, insider Julie Brown purchased 19,360 shares of GSK stock in a transaction on Thursday, February 1st. The shares were acquired at an average cost of GBX 1,583 ($19.71) per share, for a total transaction of £306,468.80 ($381,512.26). Insiders have acquired 19,802 shares of company stock worth $31,381,484 in the last three months. Corporate insiders own 1.71% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.